
Rivaroxaban
Rivaroxaban is a direct oral anticoagulant backed by large trials: it was noninferior to warfarin for stroke prevention in atrial fibrillation with less brain and fatal bleeding, noninferior to standard therapy for treating DVT and PE, and, at a low dose with aspirin, cut major cardiovascular events in stable artery disease at the cost of more bleeding. High-dose vitamin E is the high-severity supplement concern; fish oil, ginkgo and chia are rated low.
Prescription medication: not a dietary supplement
This is an FDA-approved (or investigational) drug, not a supplement. It requires a prescription and medical supervision. The information below summarizes clinical-trial evidence for education only. It is not a recommendation to obtain or use it without a doctor.
Quick decision guide
May help most
Adults with atrial fibrillation, DVT or PE, recent hip or knee replacement, or stable coronary or peripheral artery disease whose prescriber recommends rivaroxaban
Common dosing range
Set by your prescriber and depends on the use: for example 20 mg once daily with the evening meal for atrial fibrillation, or 15 mg twice daily with food for 21 days then 20 mg once daily for DVT or PE
When to expect effects
The label notes that the time to onset of its therapeutic effect is short
Watch out for
Boxed warnings: stopping early raises the risk of clots and stroke, and spinal or epidural blood clots can occur with spinal anesthesia or punctures. It can cause serious or fatal bleeding, more so with aspirin, NSAIDs, other blood thinners, SSRIs and SNRIs. Not for people with prosthetic heart valves or triple-positive antiphospholipid syndrome
What is it
Rivaroxaban is a prescription blood thinner (anticoagulant) that directly blocks factor Xa, a clotting protein. It is sold as generic rivaroxaban tablets and as Xarelto tablets and oral suspension. The Xarelto label approves it to lower the risk of stroke in nonvalvular atrial fibrillation, to treat deep vein thrombosis (DVT) and pulmonary embolism (PE) and lower the risk of them coming back, to prevent clots after hip or knee replacement and in acutely ill hospitalized patients, and, together with aspirin, to lower the risk of major cardiovascular events in coronary or peripheral artery disease. It also has approved uses in children.
Is it worth it for you?
Use this as a quick fit check, not a diagnosis.
Worth considering if…
Probably skip if…
Evidence at a glance
| Goal | Effect | Best fit | Time |
|---|---|---|---|
stroke prevention in atrial fibrillation Good Evidence | Similar to warfarin for stroke, with less brain and fatal bleeding | Adults with nonvalvular atrial fibrillation at increased stroke risk | Measured as yearly event rates over the trial |
treatment of deep vein thrombosis and pulmonary embolism Good Evidence | Similar to standard therapy for recurrent clots, with less major bleeding in PE | Adults with acute symptomatic DVT or PE | Treatment lasted 3, 6 or 12 months |
preventing clots from coming back after initial treatment Good Evidence | Large; about 82% fewer recurrent clots than placebo | Adults at continued risk of recurrent DVT or PE after at least 6 months of treatment | Measured over 6 to 12 additional months |
coronary and peripheral artery disease (with aspirin) Good Evidence | Moderate; about 24% fewer major cardiovascular events, with about 70% more major bleeding | Adults with stable coronary or peripheral artery disease at low bleeding risk | Measured over a mean of 23 months |
stroke prevention in atrial fibrillation
- Effect
- Similar to warfarin for stroke, with less brain and fatal bleeding
- Best fit
- Adults with nonvalvular atrial fibrillation at increased stroke risk
- Time
- Measured as yearly event rates over the trial
treatment of deep vein thrombosis and pulmonary embolism
- Effect
- Similar to standard therapy for recurrent clots, with less major bleeding in PE
- Best fit
- Adults with acute symptomatic DVT or PE
- Time
- Treatment lasted 3, 6 or 12 months
preventing clots from coming back after initial treatment
- Effect
- Large; about 82% fewer recurrent clots than placebo
- Best fit
- Adults at continued risk of recurrent DVT or PE after at least 6 months of treatment
- Time
- Measured over 6 to 12 additional months
coronary and peripheral artery disease (with aspirin)
- Effect
- Moderate; about 24% fewer major cardiovascular events, with about 70% more major bleeding
- Best fit
- Adults with stable coronary or peripheral artery disease at low bleeding risk
- Time
- Measured over a mean of 23 months
Evidence for 4 uses
AI-assisted evidence assessment. Talk to your doctor before relying on any single supplement.
stroke prevention in atrial fibrillation
Disease adjunctIn the double-blind ROCKET AF trial, 14,264 patients with nonvalvular atrial fibrillation at increased stroke risk took rivaroxaban 20 mg a day or dose-adjusted warfarin. Stroke or systemic embolism occurred in 1.7% per year on rivaroxaban versus 2.2% per year on warfarin in the per-protocol analysis (hazard ratio 0.79), meeting noninferiority; in the intention-to-treat analysis it was not superior (2.1% vs 2.4% per year). Major and nonmajor clinically relevant bleeding was similar, but bleeding in the brain (0.5% vs 0.7%) and fatal bleeding (0.2% vs 0.5%) were less common.
Bottom line: Rivaroxaban protects against stroke in atrial fibrillation about as well as warfarin, with fewer brain bleeds.
treatment of deep vein thrombosis and pulmonary embolism
Disease adjunctTwo open-label randomized trials compared rivaroxaban alone (15 mg twice daily for 3 weeks, then 20 mg once daily) with injected enoxaparin followed by warfarin or acenocoumarol. In 3,449 patients with DVT, recurrent clots occurred in 2.1% versus 3.0%, and in 4,832 patients with PE in 2.1% versus 1.8%; both met noninferiority. Major bleeding was lower with rivaroxaban in the PE trial (1.1% vs 2.2%), and the main bleeding outcome was similar in the DVT trial (8.1% in each group).
Bottom line: Rivaroxaban treats DVT and PE as well as the older injection-plus-warfarin approach, as a single pill.
preventing clots from coming back after initial treatment
Disease adjunctIn a double-blind continued-treatment study, 1,196 patients who had completed 6 to 12 months of treatment for a blood clot took rivaroxaban 20 mg daily or placebo for another 6 or 12 months. Recurrent clots occurred in 1.3% on rivaroxaban versus 7.1% on placebo (hazard ratio 0.18), while nonfatal major bleeding occurred in 0.7% versus none. The label's current dose for this use is 10 mg once daily, which this trial did not test.
Bottom line: Continuing rivaroxaban after a clot sharply lowers the chance of another, with a small bleeding cost.
coronary and peripheral artery disease (with aspirin)
Disease adjunctIn the double-blind COMPASS trial of 27,395 people with stable atherosclerotic disease, rivaroxaban 2.5 mg twice daily plus aspirin lowered cardiovascular death, stroke or heart attack compared with aspirin alone (4.1% vs 5.4%; hazard ratio 0.76) over a mean of 23 months, but major bleeding rose (3.1% vs 1.9%). Intracranial and fatal bleeding did not differ significantly. Rivaroxaban 5 mg twice daily alone was not better than aspirin and caused more major bleeding.
Bottom line: Low-dose rivaroxaban plus aspirin prevents more heart events than aspirin alone, at the price of more bleeding.
How it works
How to take it
What to track
Bottom line: Your prescriber sets the dose; take it daily as directed (15 and 20 mg with food), never stop on your own, and check every supplement for bleeding risk.
Safety
Know the common side effects, key cautions, and who should avoid it.
Common side effects
Serious risks
Stopping early increases the risk of blood clots (boxed warning). In atrial fibrillation trials, more strokes occurred during the switch from rivaroxaban to warfarin; the label says to consider another anticoagulant if it is stopped for any reason other than bleeding or a completed course.
Spinal or epidural blood clots (boxed warning) in people having spinal or epidural anesthesia or a spinal puncture, which can cause long-term or permanent paralysis. Risk is higher with indwelling epidural catheters, NSAIDs, platelet inhibitors or other anticoagulants, and repeated or traumatic punctures.
Serious or fatal bleeding in any organ. Risk rises with aspirin, P2Y12 platelet inhibitors, other antithrombotics, NSAIDs, SSRIs and SNRIs. Routine clotting tests do not reliably measure its effect.
Higher rates of death and bleeding after transcatheter aortic valve replacement (TAVR) in the GALILEO study, and more recurrent clots than warfarin-type drugs in triple-positive antiphospholipid syndrome.
Who should avoid it
- People with active pathological bleeding or a severe hypersensitivity reaction to rivaroxaban (contraindicated)
- People with prosthetic heart valves, including after TAVR (not recommended)
- People with triple-positive antiphospholipid syndrome (not recommended)
- People with moderate or severe liver impairment (Child-Pugh B or C) or liver disease with a clotting problem, and, for most uses, people with creatinine clearance below 15 mL/min
Pregnancy & breastfeeding
Pregnancy: the Xarelto label says the limited data in pregnant women are not enough to determine a drug-associated risk of birth defects or miscarriage, that rivaroxaban crossed the human placenta in a laboratory model, and that it should be used with caution because of the potential for pregnancy-related bleeding and emergency delivery; its effect cannot be reliably monitored with standard lab tests and dosing in pregnancy has not been studied. Anyone who could become pregnant should discuss pregnancy planning with their doctor. Breastfeeding: rivaroxaban has been found in human milk, and there are not enough data on its effects on the breastfed child or on milk production; the label says to weigh the benefits of breastfeeding against the mother's need for treatment.
Interactions
High-dose vitamin E can make platelets less sticky and may add to the bleeding risk of blood thinners. In an observational study of 566 people with atrial fibrillation taking warfarin-type blood thinners, those with higher blood vitamin E levels had more bleeding; the authors said further study is needed to see whether this holds for newer anticoagulants such as rivaroxaban. Do not start high-dose vitamin E without asking your prescriber; vitamin E from food is not the concern.
The label says to avoid these combinations because they raise rivaroxaban levels and may increase bleeding risk. People with reduced kidney function should also not take it with combined P-gp and moderate CYP3A blockers such as erythromycin unless the benefit justifies the risk. Make sure every prescriber knows you take rivaroxaban.
The label says to avoid these combinations because they lower rivaroxaban levels and may increase the risk of clots and stroke. Ask your prescriber before starting any of them.
The label says these increase bleeding risk with rivaroxaban and to avoid other anticoagulants unless the benefit outweighs the risk. Aspirin is part of the prescribed regimen for coronary and peripheral artery disease, but ask your pharmacist before using any over-the-counter pain reliever.
The Xarelto label says to avoid St. John's wort, which it names among the combined P-gp and strong CYP3A inducers that lower rivaroxaban levels and may increase the risk of clots and stroke. In two studies of 12 healthy volunteers each, St. John's wort lowered rivaroxaban exposure by 24% and 25%, and in one its anti-clotting effect fell by 20%. Do not stop rivaroxaban; tell your prescriber if you take the herb, whose enzyme effect took about a week to wear off after stopping in one study.
Omega-3 fats have a mild effect on platelets, so in theory they add to an anticoagulant. In a randomized trial of 1,516 heart-surgery patients given high-dose fish oil around surgery, major bleeding was not higher than with placebo and fewer units of blood were transfused; the trial did not report results for people taking rivaroxaban. Tell your prescriber what omega-3 products and amounts you take, and ask before starting prescription-strength doses.
Ginkgo has mild antiplatelet activity, so the pair was thought to raise bleeding risk. In a study of 41 healthy adults, 240 mg of a standardized ginkgo extract (EGb 761), as a single dose or for 8 days, did not change rivaroxaban levels or its anti-factor Xa effect and caused no bleeding events. Results may differ for other ginkgo products or for people with other bleeding risks, so tell your prescriber or pharmacist before combining them.
Chia contains plant omega-3 and fiber. In a 12-week trial in 20 adults with type 2 diabetes, about 37 g of chia a day lowered von Willebrand factor, a clotting protein, without changing blood-clotting safety tests; no study has tested chia with rivaroxaban. Treat chia as a normal food, keep intake steady, and mention a daily chia habit to your doctor or pharmacist.
Documented interactions
Evidence-graded pair pages with sources, dosing notes, and timing guidance, a complement to the narrative section above.
Warnings (3)
+ st. john's wort
highSt. John's wort speeds up CYP3A4 and P-glycoprotein, the enzyme and the transporter that clear rivaroxaban, so rivaroxaban levels fall and its protection against clots may weaken. The Xarelto label says to avoid rivaroxaban with drugs that are combined P-gp and strong CYP3A inducers and names St. John's wort among them. In two small studies, each in 12 healthy volunteers, St. John's wort lowered rivaroxaban exposure by 24 and 25 percent, and in one of them its anti-clotting effect (factor Xa inhibition) fell by 20 percent; no study has measured clots or strokes from the pair.
+ fish oil
lowOmega-3 fatty acids in fish oil have a mild effect on platelets, and rivaroxaban blocks Factor Xa to reduce clotting, so the combination is additive in theory. In a randomized trial of 1,516 heart-surgery patients, high-dose fish oil around surgery did not increase major bleeding compared with placebo and fewer units of blood were transfused; the trial did not report results for people taking rivaroxaban, and no study has tested fish oil with rivaroxaban itself.
+ ginkgo
lowRivaroxaban is a Factor Xa inhibitor and ginkgo has mild antiplatelet activity, so combining them was theorized to add to bleeding risk. However, a controlled trial in healthy subjects found standardized EGb 761 ginkgo extract did not change rivaroxaban's pharmacokinetics, anti-Factor Xa activity, or coagulation parameters, and caused no bleeding-related adverse events.
Choosing a product
What to look for on the label, and what to be skeptical of.
Look for…
Be skeptical of…
Frequently asked questions
Can I take vitamin E with rivaroxaban?⌄
This page rates high-dose vitamin E supplements a high-severity interaction. Vitamin E can make platelets less sticky, and higher vitamin E levels were linked to more bleeding in an observational study of people taking warfarin-type blood thinners; whether this applies to rivaroxaban is not known. Ask your prescriber before starting a vitamin E supplement. Vitamin E from food is not the concern.
Is fish oil safe with rivaroxaban?⌄
This page rates it low severity. A large trial found high-dose fish oil did not increase bleeding around heart surgery, though the trial did not report results for people taking rivaroxaban. Tell your prescriber the omega-3 products and amounts you take, and ask before prescription-strength doses.
Can I take ginkgo with rivaroxaban?⌄
In a study of 41 healthy adults, a standardized ginkgo extract did not change rivaroxaban levels or its blood-thinning effect. This page rates it low severity, but other products and people with other bleeding risks may differ, so check with your prescriber or pharmacist first.
Do I need to avoid vitamin K foods like leafy greens?⌄
Not the way people on warfarin are told to. Rivaroxaban blocks factor Xa directly instead of working through vitamin K, and the label notes that even vitamin K given as a medicine is not expected to change its effect. Ask your prescriber if you have questions about your diet.
Can I take ibuprofen with rivaroxaban?⌄
The label says NSAIDs such as ibuprofen and naproxen, aspirin and other blood thinners increase bleeding risk with rivaroxaban. Ask your pharmacist or prescriber before using any over-the-counter pain reliever.
What if I miss a dose of rivaroxaban?⌄
It depends on your schedule. On once-daily dosing, the label says to take the missed dose right away and never to take two doses in the same day to make up for it. On 15 mg twice daily, take it right away so you get 30 mg that day. On 2.5 mg twice daily, skip it and take the next dose on time. Never stop on your own.
References by claim
stroke prevention in atrial fibrillation
Patel et al., 2011 · PubMed (2011) link
treatment of deep vein thrombosis and pulmonary embolism
coronary and peripheral artery disease (with aspirin)
Eikelboom et al., 2017 · PubMed (2017) link
Safety
Xarelto (rivaroxaban) prescribing information · DailyMed (FDA label) link
Interaction: Vitamin E (high-dose supplements)
Pastori et al., 2013 · PMC (2013) link
Interaction: Fish oil (omega-3)
Akintoye et al., 2018 · PMC (2018) link
Interaction: Ginkgo
Hoerr et al., 2022 · PMC (2022) link
Interaction: Chia seeds
Vuksan et al., 2007 · PubMed (2007) link
Track Rivaroxaban with Pilora
Set up dose reminders, check interactions, and join the community in the Pilora app.
Disclaimer: This page summarizes published clinical-trial data for educational purposes and is not medical advice or a recommendation to use this prescription medication. Dosing, eligibility, and monitoring must be decided by a licensed prescriber.
